Kornimate/medical-research-clean huggingface dataset:
feasibility trial using an inpatient insulin dosing calculator

Conditions: Diabetes Mellitus, Type 2

Summary: the goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission. the main questions it aims to answer are: * whether using this calculator leads to no excessive hypoglycemia? * whether using this calculator leads to a decrease of hyperglycemia? participants will receive initial insulin doses by the calculator on hospital admission, and the rest of care will follow standard of care. participants will be compared with patients in the uw observational cohort who received initial insulin doses by standard of care.


Eligibility criteria:
inclusion criteria: * patients who are admitted to university of washington medical centers * with history of type 2 and/or steroid-induced diabetes mellitus * receiving insulin therapy prior to admission exclusion criteria: * patients who are admitted to icu or obstetrics ward * patients who are admitted for elective surgery or procedure * patients who present with diabetic ketone acidosis, hyperosmolar hyperglycemic state or require intravenous insulin infusion * patients who have no meal intake for 24 hours prior to admission, or planned nothing per oral (npo) during the first 24 hours after admission * patients who report low appetite (25% or less) on admission or have a significantly decreased level of consciousness that they unlikely eat right after admission * patients who receive enteral feeding after admission
the diagnostic value of 18f-fet pet/mri for cns tumors in children and adolescents

Conditions: Positron-Emission Tomography; Brain Neoplasms, Childhood

Summary: to investigate the diagnostic value of 18f-fet pet/mri instead of mri alone, children and adolescents with tumor in brain or spinal cord are included and scanned primarily at our hybrid pet/mri using the amino acid analog 18f-fet. the scans are performed at primary diagnosis, before radiation therapy, before and after operation, when relapse is suspected and three or six months after initiation of chemotherapy.

background. tumors in the brain and spinal cord are among the most common causes of death and disability by cancer in children and adolescents. mri is used for primary diagnosis as well as follow-up but is often challenged by tissue changes caused by the treatment. the amino acid analog 18f-fet is used increasingly in adults to delineate tumor and discriminate tumor from treatment effects. a hybrid pet/mri scanner enables the simultaneous imaging with pet and mri, which is important in especially the younger children needing anaesthesia to cooperate to the procedure. aim the aim of the study is to compare diagnostics using mri alone with 18f-fet pet/mri (or sequential mri and pet) in children and adolescents diagnosed with a central nervous system (cns) tumor before the age of 18 years. the scans will be performed at primary diagnosis/before operation/biopsy, within 72 hours after operation, planning radiation therapy, evaluation of treatment effect, when relapse is suspected. exclusion criteria are mri contraindications, pregnancy, or a syndrome with increased sensitivity to radiation. the investigators wish to evaluate which cases and for which tumor types, 18f-fet pet/mri will increase sensitivity and specificity of diagnosing cns tumors. side effects the side effects are mainly the side effect from the mri with venous puncture, the mri contrast leading that can lead to shortlived nausea or headache, fasting for 6 hours and the radioactivity exposure of 4.2 msv (1,4 times the early background radiation) for each scan procedure. the maximal number of scans in the project is 3, 6 or 10 depending on the diagnosis. data analysis the correlation between 18f-fet uptake in tumor and tumor grading (obtained from operation/biopsy) will be investigated. when relapse is suspected, sensitivity and specificity for recurrence/progression for mri alone versus pet/mri will be compared. it will be analysed if the addition of pet influences the diagnosis/chosen treatment. a major impact of 6% will be regarded significant. the prognostic value of 18f-fet uptake after treatment will be investigated.

Eligibility criteria:
inclusion criteria: * suspicion of newly diagnosed cns tumor, recurrence or radiation therapy planning * age \<18 years at first ct/mri suggesting cns tumor * written informed consent from parents (age \ 18 years) exclusion criteria: * contraindications for mri (e.g. metal implants) * pregnancy * known syndrome with increased sensitivity to radiation (e.g. gorlin or ataxia telangiectasia

Keywords: fet pet/mri child
dietary intervention to improve fertility in women with endometriosis undergoing ivf

Conditions: Endometriosis

Summary: the goal of this randomized controlled trial is to assess whether a 12-week anti-inflammatory diet can improve fertility outcomes in women with endometriosis undergoing in vitro fertilization (ivf). the main questions are: * does the anti-inflammatory diet reduce the rate of inadequate ovarian response to hormonal stimulation (retrieval of ≤3 oocytes)? * does it improve secondary outcomes such as embryo quality, pregnancy rates, inflammation markers, and quality of life? researchers will compare two groups: * women receiving standard ivf protocols. * women undergoing the same ivf protocol plus the anti-inflammatory diet. participants will: * be randomized into one of the two groups. * follow dietary counseling sessions and complete dietary assessments (diet group). * provide biological samples (e.g., plasma, vaginal and fecal swabs, and follicular fluid) before and after the dietary intervention to evaluate potential differences in inflammation, hormonal levels, and microbiome composition between the two groups and across timepoints (pre- and post-diet). * complete questionnaires on quality of life, sexual function, and symptomatology severity before and after the intervention to assess differences between the two groups and across timepoints.

women who agree to participate in the study will be randomized into two groups: one group will receive standard ivf protocols, and the other will undergo a 12-week anti-inflammatory diet followed by the standard ivf protocol. in both groups, participants' dietary habits will be monitored throughout the study period to detect any variations. the primary outcome will be to compare the rate of inadequate ovarian response to hormonal stimulation (defined as the retrieval of ≤3 oocytes according to the poseidon 2016 criteria) in infertile women with endometriosis.

Eligibility criteria:
inclusion criteria: * age \< 40 years * pregnancy seeking for more than 12 months * regular menstrual cycle, i.e. mean cycle interval between 21 and 35 days * ultrasonographic diagnosis of ovarian endometriomas or deep peritoneal endometriosis. * antral follicle counts (afc) ≥ 5 (no other cause of reduced ovarian reserve). * absence of ureteral stenosis or intestinal subocclusive symptoms exclusion criteria: * contraindication to pregnancy * hydrosalpinx * endometriomas with a mean diameter \> 4 cm * submucosal fibroids or large intramural or subserosal fibroids (≥ 5 cm). * doubtful sonographic findings that do not allow to reliably rule out malignancy. * severe male factor (\<1 million sperm/ml)

Keywords: ivf endometriosis anti-inflammatory diet
the stem cell-derived extracellular vesicle therapy in acute ischemic stroke (stevia)

Conditions: Acute Ischemic Stroke AIS

Summary: this is a multicenter open-label, single-arm, dose escalation phase i clinical trial to evaluate the safety and tolerability of sne-101 in patients with acute ischemic stroke

the study aims to assess the safety, tolerability, and preliminary efficacy of allogeneic wharton's jelly-mesenchymal stem cell-derived extracellular vesicles (evs) in patients with acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * adults with 19 years or older * onset of symptoms within 2 to 5 days * imaging findings must meet both of the following: * infarction within the middle cerebral artery territory on diffusion-weighted imaging (dwi) * infarct size ≥ 20 mm in the longest diameter on dwi * neurological status meeting all three of the following nihss criteria: * moderate to severe neurological deficit (nihss score between 5-21) * new onset of motor weakness (score 2-4 in at least one of nihss items 5a, 5b, 6a, or 6b) * no impaired consciousness (score 0-1 on nihss items 1a, 1b, and 1c) * voluntary written informed consent exclusion criteria: subjects are ineligible if they meet any of the following: * pre-stroke disability (pre-stroke mrs ≥ 2) * likely to recover spontaneously, based on all three of: * no longer meeting the nihss inclusion criteria 48 hours post-thrombolysis or endovascular therapy * lacunar stroke due to small vessel occlusion * safe (shoulder abduction and finger extension) score ≥ 5 * presence or risk of malignant middle cerebral artery infarction with brain edema * significant medical history within the past 5 years: * severe heart failure * severe infectious disease * severe hepatic failure or renal failure * newly diagnosed or actively treated cancer * any systemic disease deemed by investigator to significantly reduce life expectancy * any condition likely to hinder follow-up during the study * diagnosed severe psychiatric illness: * moderate or greater depression pre-stroke with functional impairment and suicide risk * pre-stroke dementia interfering with daily living (cdr ≥ 2) * contraindication to mri (e.g., pacemaker) * pregnant or breastfeeding, or unwilling to use effective contraception method for 90 days after last dose. * participation in another clinical trial within the past 3 months * any other reason determined by the investigator that would prevent participation

Keywords: stroke exosome extracellular vesicles wharton's jelly-mesenchymal stem cell msc
prevention of postoperative delirium after acute surgery

Conditions: Postoperative Delirium

Summary: the aim of this trial is to evaluate the implementation and effect of an evidence based, multicomponent intervention on postoperative delirium, when fast implemented throughout the patients stay in hospital before, during and after acute surgery in a risk population, the primary outcome being frequency of patients with positive confusion assessment method (cam) score. the hypothesis is that the frequency of postoperative delirium will be reduced after implementation of the preventive interventions.


Eligibility criteria:
inclusion criteria: * patients aged 40 or above. * patients scheduled for acute abdominal or orthopaedic surgery in general anaesthesia with an expected duration of 30 minutes or more. * patients who are scheduled for surgery within 72 hours of hospital admission. * patients who are expected to stay in hospital for 24 hours or more. exclusion criteria: * patients screened cam positive before surgery. * patients who have already been included in the study * patients unable to speak and read danish. * inability to provide consent.

Keywords: implementation prevention multicomponent intervention anaesthetics, general non-cardiac acute surgery non-pharmacological intervention postoperative care
the role of preoperative melatonin in reducing the inhaled isoflurane requirements in open nephrectomy

Conditions: Postoperative Pain

Summary: melatonin is a hormone that the pineal gland in the brain produces. melatonin fulfills many functions in the body but it is mostly known for maintaining a circadian rhythm that is governed by the central circadian pacemaker (biological clock) in the suprachiasmatic nuclei in the hypothalamus. melatonin works by attaching to receptors or nerve endings in the suprachiasmatic nucleus (scn) in the hypothalamus. it binds to melatonin receptor 1 and melatonin receptor 2, commonly referred to as mt1 and mt2. people can take it as a natural or synthetic supplement to promote restful sleep. melatonin showed promise for preventing shifts in sleep and wake times in people with jetlag and improving sleep in people with insomnia. it can also be used for headaches, cancer, and alzheimer's disease. melatonin can be used as an analgesic, sedative, and hypnotic drug that can distinguish it as an attractive alternative premedicant

a study that was done before in j anaesth by borazan h et al revealed that postoperative pain score in patients undergoing radical prostatectomy who received melatonin one hour before surgery as a premedication was significantly lower than the control group with a significant p-value( less than 0.05). the entropy is indicated for adult and pediatric patients older than 2 years intraoperatively for monitoring the electric state of the brain. in adult patients, state entropy and response entropy can be used as an aid in monitoring the effects of certain anaesthetic agents which will help the user to titrate the anaesthetic agent according to the individual needs of each patient. furthermore, the use of entropy parameters may be associated with a reduction of anaesthetic use and faster emergence of anaesthesia. the entropy measurement is to be used as an adjunct to other physiological parameters. to the best of investigators knowledge, there is no study that examined the effect of melatonin on inhaled isoflurane requirements intraoperatively. so, in this study, the effect of melatonin will be assessed on intraoperative inhaled isoflurane requirements in patients undergoing open nephrectomy under general anaesthesia by using entropy

Eligibility criteria:
inclusion criteria: * patients undergoing nephrectomy under general anesthesia aged from 20 to 60 years. * asa 1 or 2. * bmi 25 to 30 exclusion criteria: * patients with uncontrolled hypertension. * patients presenting with (ihd, significant arrhythmias, heart failure). * allergy to melatonin. * history of epileptic seizures, psychoactive medications, neurological disorders or trauma.
duke spine outcome study (dsos)

Conditions: Spinal Tumor; Spinal Disorder

Summary: the primary goal of this registry is to increase the knowledge about spine tumors and other spine disorders to guide appropriate management strategies for the future. this registry will include the review of medical records, data collection for health related quality of life questionnaires, and collected tissues and samples. the study will require obtaining spinal lesions (tumor, etc.), blood, and bone marrow samples (from non-lesional bone) from selected patients, which will be collected during your surgery.


Eligibility criteria:
inclusion criteria: * age between 18 and 85 years. * able to read and write local language at an elementary level. * diagnosis of primary or metastatic tumor of the spine ); or * infection of the spine; or * instability of the spine; or * injury of the spine. * accessibility for treatment and follow up. * patient consent obtained according to duke institutional policy. inclusion criteria for spine surgery (control population for bone marrow specimens) * age between 18 and 85 years. * spine surgery to be performed at duke university medical center (dumc) under the auspices of the neurosurgery program. * no concurrent cancer diagnosis. * accessibility for treatment and follow up. * patient consent obtained according to duke institutional policy. exclusion criteria: * history of substance abuse (recreational drugs, alcohol) within 12 months prior to screening * is a prisoner. * a disease or condition that would, in opinion of the investigator, preclude accurate evaluation (e.g. significant psychiatric disease), or that would impair the ability of the patient to receive protocol treatment or comply with protocol. * pregnant or breast feeding during the study period (women of child-bearing potential will require a negative serum pregnancy test within 30 days of enrollment). * active infection, or fever of unknown origin. * inflammatory bowel disease. * systemic lupus erythematosus. * rheumatoid arthritis, or other autoimmune disease. * history of or active hematologic or bone marrow diseases, including but not limited to diagnosed lymphomas, leukemias, sickle cell or other anemias not associated with their current condition. * polycythemia vera. * known or suspected immunodeficiency or human immunodeficiency virus (hiv). * hematocrit \< 24% pre-operatively.
mycobiome supporting diet to reduce gi toxicity associated with asct

Conditions: Autologous Transplant; Myeloma

Summary: the purpose of this study is to determine if this specific mycobiome supporting diet (msd diet) can help reduce gut inflammation during post-transplant period. the msd is an special diet which will be explained in detail by a dietician that works by supporting the body's good gut bacteria and fungi.

this is a non-randomized cohort study. participants will be on a specific diet for 4 weeks prior to transplant and 10 days after transplant, and will then be asked to fill out several questionnaires during this period to see if this diet is easy and simple to follow. the questionnaires will be weekly while participants are outpatient and once admitted to the hospital, participants will need to fill it on the last day (10 days after stem cell infusion). participants will also be requested to provide fecal swab samples which we will test for bacteria and fungi. a total of 3 samples will be taken at different time points during this study.

Eligibility criteria:
inclusion criteria: * eligible for first autologous transplant for myeloma * willing to adhere to the allowed and disallowed foods of the diet plan. * able to get and prepare their own food items for all meals during the study exclusion criteria: * active inflammatory bowel disease, celiac disease, other chronic intestinal disorders * pregnant women, planning to get pregnant or breastfeeding * prior bowel resection * inability to tolerate the study diet due to allergies/ intolerance/ preference * inability to consent to trial * patients with restrictions in diet including inability to have oral nutrition with regular consistency * any condition that the investigator feels may limit the volunteer's ability to complete the study protocol. * patients with absolute neutrophil count (anc) \< 1000 on long term antibacterial prophylaxis ongoing 3 days prior to enrollment * patients who received antifungal therapy in 3 days prior to enrollment * patients who received steroid therapy in 7 days prior to enrollment
cardiac output and recovery time

Conditions: Residual Neuromuscular Blockade

Summary: the purpose of this research is to determine the time it takes to reverse the effects of the intraoperative medication given to relax the muscles and how this period of recovery correlates with a function of the heart.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years old. * patients willing to participate and provide an informed consent. * patients undergoing an elective surgical procedure requiring administration of rocuronium, and the use of a pulmonary artery catheter intraoperatively. exclusion criteria: * patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, dupuytren contracture. * patients with systemic neuromuscular diseases such as myasthenia gravis. * patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal impairment or end-stage liver disease. * patients having surgery that would involve prepping the arm or leg into the sterile field.

Keywords: neuromuscular blockade tetragraph amg emg
ultrasound-guided percutaneous microwave ablation for benign thyroid nodules

Conditions: Thyroid Nodule

Summary: percutaneous microwave ablation(mwa) was reported as an effective modality for the management of thyroid nodules(tns). this study aims to validate mwa as a feasible approach for patients with tns for whom surgery is contraindicated or refused. two groups of subjects with tns(one group to treat with mwa and the other group to receive regular ultrasonic follow-up without any treatment) will be evaluated in term of tn volume, ultrasonic image and clinical symptoms.


Eligibility criteria:
inclusion criteria: * age\>18 years * benign thyroid nodules(typ 2) * solid or predominantly solid(colloid component\ 3.0ml) thyroid nodules * refusal and/or inefficacy of surgery exclusion criteria: * pregnancy * malignant or suspicious thyroid nodules

Keywords: thyroid nodule microwave ablation
post-marketing surveillance study for the safety of efluelda tetra pre-filled syringe.

Conditions: Immunization; Influenza (Healthy Volunteers)

Summary: to investigate the incidence of adverse events (aes) and adverse drug reactions (adrs) occurred following administration of efluelda tetra in adults aged 65 years or older under routine clinical practice, as per approved indications. the study duration of each participation will be approximately 28 to 35 days. in the event that visit 2 is not made, the study duration would be extended to 36 to 42 days.


Eligibility criteria:
inclusion criteria: * adults aged 65 years or older on the day of enrollment * the informed consent form has been signed and dated * receipt of 1 dose of efluelda tetra on the day of enrollment according to the approved local product label exclusion criteria: * previous history of enrollment in this study * participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device or medical procedure
epidemiological study on malignancy complicated with renal injury

Conditions: Kidney Injury

Summary: the epidemiological study of tumor complicated with kidney disease can clarify the prevalence and risk factors of renal injury when malignant tumor is diagnosed, and understand the impact of malignant tumor complicated with renal injury on survival time. this study will bring enlightenment to clinicians, discover high-risk factors in time, and try to avoid renal damage factors in diagnosis and treatment. early diagnosis and early treatment can partially terminate the progress of renal injury, avoid the suspension of treatment due to renal reasons, and avoid the occurrence of end-stage renal failure (esrd).

1. to determine the prevalence of malignant tumor complicated with renal injury and analyze the related risk factors. 2. to compare the survival time of malignant tumor with or without renal injury

Eligibility criteria:
inclusion criteria: * malignancy confirmed by pathology. * between 18-80 years old, regardless of gender; patients initially diagnosed with malignant tumors in our hospital from july 2017 to june 2021; waiver of informed consent. exclusion criteria: * patients with benign tumor diagnosed by pathology; the patient refused to participate; patients judged by other researchers as unsuitable for inclusion in the study.